Drug General Information
Drug ID
D04SLF
Former ID
DCL000497
Drug Name
Bevacizumab + Trastuzumab
Drug Type
Antibody
Indication Metastatic breast cancer [ICD10:C50] Phase 3 [532301]
Breast cancer [ICD9: 174, 175; ICD10:C50] Phase 2 [554002]
Company
Roche
Structure
Download
2D MOL

3D MOL

Formula
C24H40O3
PubChem Compound ID
Target and Pathway
Target(s) Vascular endothelial growth factor Target Info Inhibitor [551607]
Receptor protein-tyrosine kinase erbB-2 Target Info [551607]
KEGG Pathway ErbB signaling pathway
Calcium signaling pathway
HIF-1 signaling pathway
Focal adhesion
Adherens junction
Pathways in cancer
Proteoglycans in cancer
MicroRNAs in cancer
Pancreatic cancer
Endometrial cancer
Prostate cancer
Bladder cancer
Non-small cell lung cancer
Central carbon metabolism in cancer
NetPath Pathway TCR Signaling Pathway
PANTHER Pathway Cadherin signaling pathway
EGF receptor signaling pathway
Pathway Interaction Database ErbB4 signaling events
ErbB2/ErbB3 signaling events
ErbB receptor signaling network
a6b1 and a6b4 Integrin signaling
Validated targets of C-MYC transcriptional repression
PathWhiz Pathway Phosphatidylinositol Phosphate Metabolism
Reactome SHC1 events in ERBB2 signaling
PLCG1 events in ERBB2 signaling
PIP3 activates AKT signaling
GRB2 events in ERBB2 signaling
PI3K events in ERBB2 signaling
Constitutive Signaling by Aberrant PI3K in Cancer
Sema4D induced cell migration and growth-cone collapse
RAF/MAP kinase cascade
WikiPathways DNA Damage Response (only ATM dependent)
ErbB Signaling Pathway
EGF/EGFR Signaling Pathway
Focal Adhesion
Extracellular vesicle-mediated signaling in recipient cells
Bladder Cancer
Signaling by ERBB2
Integrated Pancreatic Cancer Pathway
Signaling Pathways in Glioblastoma
Leptin signaling pathway
miR-targeted genes in muscle cell - TarBase
Semaphorin interactions
References
Ref 532301AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. J Clin Oncol. 2013 May 10;31(14):1719-25.
Ref 554002ClinicalTrials.gov (NCT00365365) Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer
Ref 551607Clinical pipeline report, company report or official report of Roche (2009).

If you find any error in data or bug in web service, please kindly report it to Dr. Wang and Dr. Li.